U.S.: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in the U.S.

The U.S. prophylactic medicaments containing insulin market rose significantly to $X in 2022, growing by X% against the previous year. Over the period under review, consumption enjoyed resilient growth. Prophylactic medicaments containing insulin consumption peaked at $X in 2020; however, from 2021 to 2022, consumption stood at a somewhat lower figure.

Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses in the U.S.

In value terms, prophylactic medicaments containing insulin production rose remarkably to $X in 2022. Over the period under review, production showed a strong expansion. The pace of growth appeared the most rapid in 2015 when the production volume increased by X%. Prophylactic medicaments containing insulin production peaked at $X in 2020; however, from 2021 to 2022, production stood at a somewhat lower figure.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports from the U.S.

After two years of decline, overseas shipments of medicaments containing insulin but not antibiotics in measured doses increased by X% to X tons in 2022. In general, total exports indicated a measured increase from 2012 to 2022: its volume increased at an average annual rate of X% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. As a result, the exports attained the peak and are likely to continue growth in the immediate term.

In value terms, prophylactic medicaments containing insulin exports soared to $X in 2022. Over the period under review, exports saw buoyant growth. As a result, the exports attained the peak and are likely to continue growth in the immediate term.

Exports by Country

Denmark (X tons) was the main destination for prophylactic medicaments containing insulin exports from the United States, accounting for a X% share of total exports. Moreover, prophylactic medicaments containing insulin exports to Denmark exceeded the volume sent to the second major destination, Japan (X tons), twofold. Mexico (X tons) ranked third in terms of total exports with a X% share.

From 2012 to 2022, the average annual rate of growth in terms of volume to Denmark totaled X%. Exports to the other major destinations recorded the following average annual rates of exports growth: Japan (X% per year) and Mexico (X% per year).

In value terms, the largest markets for prophylactic medicaments containing insulin exported from the United States were Canada ($X), Mexico ($X) and Denmark ($X), with a combined X% share of total exports. Brazil, Japan, Spain, Pakistan and Germany lagged somewhat behind, together accounting for a further X%.

In terms of the main countries of destination, Spain, with a CAGR of X%, recorded the highest rates of growth with regard to the value of exports, over the period under review, while shipments for the other leaders experienced more modest paces of growth.

Export Prices by Country

In 2022, the average prophylactic medicaments containing insulin export price amounted to $X per ton, waning by X% against the previous year. Over the period under review, export price indicated a pronounced expansion from 2012 to 2022: its price increased at an average annual rate of X% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, prophylactic medicaments containing insulin export price increased by X% against 2018 indices. The growth pace was the most rapid in 2020 when the average export price increased by X%. Over the period under review, the average export prices reached the peak figure at $X per ton in 2021, and then declined in the following year.

There were significant differences in the average prices for the major overseas markets. In 2022, amid the top suppliers, the country with the highest price was Canada ($X per ton), while the average price for exports to Denmark ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was recorded for supplies to Canada (X%), while the prices for the other major destinations experienced more modest paces of growth.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports into the U.S.

In 2022, supplies from abroad of medicaments containing insulin but not antibiotics in measured doses increased by X% to X tons, rising for the third year in a row after three years of decline. The total import volume increased at an average annual rate of X% from 2012 to 2022; however, the trend pattern indicated some noticeable fluctuations being recorded throughout the analyzed period. The growth pace was the most rapid in 2016 with an increase of X% against the previous year. As a result, imports attained the peak of X tons. From 2017 to 2022, the growth of imports remained at a lower figure.

In value terms, prophylactic medicaments containing insulin imports declined to $X in 2022. Over the period under review, imports, however, continue to indicate a deep setback. The pace of growth was the most pronounced in 2014 when imports increased by X% against the previous year. As a result, imports reached the peak of $X. From 2015 to 2022, the growth of imports remained at a somewhat lower figure.

Imports by Country

In 2022, Germany (X tons) constituted the largest supplier of prophylactic medicaments containing insulin to the United States, accounting for a X% share of total imports. Moreover, prophylactic medicaments containing insulin imports from Germany exceeded the figures recorded by the second-largest supplier, Malaysia (X tons), fivefold. France (X tons) ranked third in terms of total imports with a X% share.

From 2012 to 2022, the average annual rate of growth in terms of volume from Germany was relatively modest. The remaining supplying countries recorded the following average annual rates of imports growth: Malaysia (X% per year) and France (X% per year).

In value terms, Germany ($X) constituted the largest supplier of medicaments containing insulin but not antibiotics in measured doses to the United States, comprising X% of total imports. The second position in the ranking was held by France ($X), with a X% share of total imports. It was followed by Denmark, with a X% share.

From 2012 to 2022, the average annual growth rate of value from Germany amounted to X%. The remaining supplying countries recorded the following average annual rates of imports growth: France (X% per year) and Denmark (X% per year).

Import Prices by Country

In 2022, the average prophylactic medicaments containing insulin import price amounted to $X per ton, waning by X% against the previous year. Over the period under review, the import price showed a abrupt shrinkage. The pace of growth was the most pronounced in 2014 an increase of X%. As a result, import price reached the peak level of $X per ton. From 2015 to 2022, the average import prices remained at a lower figure.

Prices varied noticeably by country of origin: amid the top importers, the country with the highest price was Denmark ($X per ton), while the price for Malaysia ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Malaysia (X%), while the prices for the other major suppliers experienced a decline.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :